Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts

J Hepatol. 2001 May;34(5):711-5. doi: 10.1016/s0168-8278(00)00101-x.

Abstract

Background/aims: The tumour necrosis factor (TNF)-2 promoter allele, which elicits elevated expression of TNF-alpha, is in linkage disequilibrium with the extended haplotype HLA-A1-B8-DR3-DQ2. TNF-2 and HLA-DR3 have been implicated in renal and cardiac graft rejection and loss. Cytomegalovirus (CMV) infection has been associated with chronic allograft rejection. We examined the relationship between HLA-DR3, promoter allele TNF-2 and cytomegalovirus in relation to chronic rejection following liver transplantation.

Methods: (i) Retrospective analysis of HLA-DR3 was performed in 307 liver transplant recipients and 283 donors. (ii) Prospective analysis of TNF-alpha promoter allele status, HLA-DR3 status and cytomegalovirus infection was assessed in 123 recipients.

Results: (i) Retrospective analysis. Recipient HLA-DR3 (relative risk 1.9; 95% C.I. 1.01-3.58) was a risk factor for chronic rejection. (ii) Prospective analysis. Recipient HLA-DR3 was a risk factor for chronic rejection (relative risk 3.41; 95% C.I. 1.66-7.03) which was elevated further by superimposed CMV infection (relative risk 5.01; 95% C.I. 2-12.55). Recipient TNF-2 was associated with chronic rejection (relative risk 2.29; 95% C.I. 0.9-5.83) through linkage to HLA-DR3.

Conclusions: Recipient HLA-DR3, TNF-2 status and CMV infection were inter-related risk factors for chronic rejection of liver grafts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alleles*
  • Chronic Disease
  • Cytomegalovirus Infections / complications*
  • Female
  • Genetic Linkage
  • Graft Rejection / etiology*
  • Graft Rejection / genetics*
  • HLA-DR3 Antigen / genetics
  • HLA-DR3 Antigen / metabolism*
  • Humans
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Promoter Regions, Genetic / genetics*
  • Prospective Studies
  • Retrospective Studies
  • Risk Factors
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • HLA-DR3 Antigen
  • TNF protein, human
  • Tumor Necrosis Factor-alpha